Morphological alterations and growth inhibition of Leishmania (L.)amazonensis promastigotes exposed to zidovudine (AZT)
- PMID: 20922414
- DOI: 10.1007/s00436-010-2096-3
Morphological alterations and growth inhibition of Leishmania (L.)amazonensis promastigotes exposed to zidovudine (AZT)
Abstract
Leishmania parasites cause a worldwide public health disease and its treatment is still based on pentavalent antimonials which present financial and toxicologic limitations. Some nucleosidic derivatives have demonstrated anti-leishmanial properties and this study aims to evaluate the in vitro morphologic alterations and growth inhibition of Leishmania (L.) amazonensis promastigotes exposed to zidovudine at several concentrations. The citotoxicity of zidovudine (AZT) to macrophages was determined by an MTT assay. After which the promastigotes were exposed to concentrations of AZT, ranging from 1 to 50 μM. The evaluation of survival and morphometry alterations were performed in two distinct phases of in vitro growth, on the third and sixth days, representing the logarithmic and stationary phases, respectively. Slides with the promastigotes were photographed and analyzed using Image J. A significant reduction of parasite number in the logarithmic phase of in vitro growth was observed when the parasites were submitted to 20, 30, 40, and 50 μM of AZT. Morphometric alterations were observed such as an increase in width of the body, cytoplasmic granulations and vacuolizations. These data indicate the toxicity of AZT which prevents the parasite's multiplication, indicating a promising use of AZT as an anti-leishmania drug.
Similar articles
-
In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.Acta Trop. 2019 Mar;191:29-37. doi: 10.1016/j.actatropica.2018.12.036. Epub 2018 Dec 23. Acta Trop. 2019. PMID: 30586571
-
In vitro evaluation of (-)α-bisabolol as a promising agent against Leishmania amazonensis.Exp Parasitol. 2015 Jan;148:66-72. doi: 10.1016/j.exppara.2014.10.001. Epub 2014 Nov 5. Exp Parasitol. 2015. PMID: 25448354
-
Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro.PLoS One. 2015 Apr 24;10(4):e0124183. doi: 10.1371/journal.pone.0124183. eCollection 2015. PLoS One. 2015. PMID: 25909893 Free PMC article.
-
Selective effects of Euterpe oleracea (açai) on Leishmania (Leishmania) amazonensis and Leishmania infantum.Biomed Pharmacother. 2018 Jan;97:1613-1621. doi: 10.1016/j.biopha.2017.11.089. Epub 2017 Nov 28. Biomed Pharmacother. 2018. PMID: 29793323
-
Antileishmanial Activity, Cytotoxicity and Mechanism of Action of Clioquinol Against Leishmania infantum and Leishmania amazonensis Species.Basic Clin Pharmacol Toxicol. 2018 Sep;123(3):236-246. doi: 10.1111/bcpt.12990. Epub 2018 Apr 6. Basic Clin Pharmacol Toxicol. 2018. PMID: 29481714
Cited by
-
Antileishmanial activity of antiretroviral drugs combined with miltefosine.Parasitol Res. 2016 Oct;115(10):3881-7. doi: 10.1007/s00436-016-5153-8. Epub 2016 Jun 1. Parasitol Res. 2016. PMID: 27249967
-
Structural and Kinetic Characterization of Thymidine Kinase from Leishmania major.PLoS Negl Trop Dis. 2015 May 15;9(5):e0003781. doi: 10.1371/journal.pntd.0003781. eCollection 2015 May. PLoS Negl Trop Dis. 2015. PMID: 25978379 Free PMC article.
-
Determination of key hub genes in Leishmaniasis as potential factors in diagnosis and treatment based on a bioinformatics study.Sci Rep. 2024 Sep 28;14(1):22537. doi: 10.1038/s41598-024-73779-w. Sci Rep. 2024. PMID: 39342024 Free PMC article.
-
Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.Front Immunol. 2018 Jan 12;8:1943. doi: 10.3389/fimmu.2017.01943. eCollection 2017. Front Immunol. 2018. PMID: 29375567 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources